Wall Street analyst estimates for Achieve Life Sciences, Inc. (ACHV): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.20 | ||
| 2026-08-11 | $-0.80 | $-0.16 | -385.2% |
| 2026-05-12 | $-0.19 | $-0.30 | +36.7% |
| 2026-03-24 | $-0.28 | $-0.27 | -3.7% |
| 2025-11-06 | $-0.28 | $-0.24 | -16.7% |
| 2025-08-07 | $-0.37 | $-0.37 | +0.0% |
| 2025-05-13 | $-0.37 | $-0.37 | +0.0% |
| 2025-03-11 | $-0.36 | $-0.30 | -20.0% |
Valuation Ratios
| Price / Book | -48.65 |
| EV / EBITDA | -7.43 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $282000 | $282000 | $254000 | $255000 | 0 | 0 | 0 | $229000 | $228000 |
| Gross Profit | $5.1M | -$282000 | -$282000 | -$254000 | -$255000 | 0 | 0 | 0 | -$229000 | -$228000 |
| Research & Development | $14.8M | $3.1M | $5.9M | $9.7M | $6.9M | $24.0M | $30.1M | $15.8M | $22.8M | $23.0M |
| Selling, General & Admin | $8.9M | $3.5M | $6.9M | $6.9M | $7.6M | $9.1M | $10.7M | $11.4M | $16.3M | $31.9M |
| Operating Expenses | $23.7M | $6.6M | $12.8M | $16.5M | $14.5M | $33.1M | $40.8M | $27.2M | $38.8M | $54.7M |
| Operating Income | -$21.2M | -$6.6M | -$12.8M | -$16.5M | -$14.8M | -$33.1M | -$40.8M | -$27.2M | -$39.1M | -$54.9M |
| EBITDA | -$19.9M | -$13.4M | -$12.4M | -$16.1M | -$14.5M | -$32.9M | -$40.3M | -$26.7M | -$37.4M | -$53.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | $1.8M | $2.9M | $2.2M | $819000 |
| Pre-tax Income | -$20.1M | -$13.6M | -$12.7M | -$16.4M | -$14.7M | -$33.2M | -$42.4M | -$29.8M | -$39.8M | -$54.6M |
| Income Tax | -$1.1M | -$3.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$20.1M | -$10.6M | -$12.7M | -$16.4M | -$14.7M | -$33.2M | -$42.4M | -$29.8M | -$39.8M | -$54.6M |
| EPS | $-1478.66 | $-441.47 | $-72.29 | $-39.15 | $-5.39 | $-4.05 | $-3.95 | $-1.50 | $-1.24 | $-1.25 |
| EPS (Diluted) | $-1474.98 | $-441.47 | $-72.29 | $-39.15 | $-5.39 | $-4.05 | $-3.95 | $-1.50 | $-1.24 | $-1.25 |
| Shares Outstanding (Diluted) | $13647 | $23972 | $175511 | $412320 | $2.7M | $8.1M | $10.6M | $19.8M | $32.1M | $43.6M |
Price
| Price | $7.42 |
| Market Cap | $762M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALLO · ARCT · AVIR · CAPR · HUMA · IMRX · SGMT
Explore sector: Healthcare · Biotechnology
More sections of ACHV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks